SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
Key Highlights
- ➤GPS cut AML death risk 41%, with median overall survival of 24.0 versus 14.7 months
- ➤REGAL met its primary endpoint with hazard ratio 0.59 and p=0.035
- ➤SELLAS plans FDA discussions and a GPS BLA submission in first half of 2027
- ➤GPS was generally well tolerated, with no new safety signals identified
Expert Statements
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS
“We are deeply grateful to the patients and their families, investigators, clinical teams, and everyone who contributed to REGAL over the course of this study. Their commitment has helped make this important milestone possible”
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission. The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for SELLAS and provides Phase 3 validation of our WT1-targeted immunotherapeutic technology. We also believe GPS has the potential to become an important paradigm-shifting option for this high-risk population that desperately needs effective therapies. Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible.”
Hagop M. Kantarjian, Javier Pinilla-Ibarz, and M. Yair Levy, Members of the REGAL Study Steering Committee
“Patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and have a significant need for new treatment approaches. The landmark data from the Phase 3 REGAL trial demonstrate a statistically significant and clinically meaningful overall survival advantage for the GPS immunotherapeutic cancer vaccine in this underserved population. By training the immune system to target residual leukemia cells, GPS addresses a critical unmet need and has the potential to redefine the treatment paradigm in AML maintenance therapy. We look forward to sharing the detailed results from REGAL with the medical community at a future scientific meeting.”
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
- Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS -
Get started
Create a free account to read the full story.
